Preclinical formulations for discovery and toxicology: physicochemical challenges
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Formulations play a key role in assessing the biological properties of a molecule during drug discovery. Maximising exposure is the primary objective in early animal experimentation, so that the pharmacokinetics, pharmacodynamics and toxicological signals can be put into context with the biological response to specific targets. Consistency in the exposure is also a key aspect, and effective formulation and drug delivery strategies are important to achieve this. Diversity in the physiology between various animal species, routes of administration and limitations posed by specific pharmacological models make formulation development that much more challenging. Poor physicochemical properties of compounds in the early stages need to be kept under consideration while screening for formulation vehicles. This review captures the various challenges posed at different stages of drug discovery for formulation of a compound to dose in animals. Approaches to formulations for various routes of administration are discussed. Limitations posed by the goals for various animal studies such as early efficacy studies, pharmacokinetic studies and toxicology studies are identified and some strategies are proposed. Physicochemical characterisations that are needed to select formulation vehicles as well as to identify potential issues are suggested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734 · cited 1×
“With the newer leads from combinatorial chemistry efforts, a significant negative impact was seen on the physicochemical properties such as lipophilicity, aqueous solubility and molecular weight [2,5], manifesting in difficulties to formulate, and, hence, most formulations were dosed suboptimally either in dimethyl su…”
BackgroundDiehl, K., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., Vidal, J., & Vorstenbosch, C. V. D. (2001) · Journal of Applied Toxicology · doi:10.1002/jat.727 · Cited by 1,562 · cited 1×
“2 Impact of administered volume on formulation selection Volume restrictions exist for each species and for each route of administration, based on toxicity studies [28,29].”
BackgroundNanosuspensions in drug delivery
Rabinow, B. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1494 · Cited by 1,524 · cited 1×
“Several examples have been reported in which these approaches have significantly improved oral bioavailability [15,58-61].”
BackgroundNanosuspensions as particulate drug formulations in therapy
Müller, R. H., Jacobs, C., & Kayser, O. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00118-6 · Cited by 1,370 · cited 1×
“(2006) 2(5) 725 significant attention [70,71].”
Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
Neslihan Gursoy, R., & Benita, S. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.02.001 · Cited by 1,358 · cited 1×
“Several strategies for lipid-based formulation approaches such as emulsions, microemulsions, self-emulsifying drug delivery systems and solid dispersions have been described [59,61,64-67].”
BackgroundEvaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs
Galia, E., Nicolaides, E., Hörter, D., Löbenberg, R., Reppas, C., & Dressman, J. B. (1998) · Pharmaceutical Research · doi:10.1023/a:1011910801212 · Cited by 927 · cited 1×
“DSC: Differential scanning calorimetry; FaSSIF: Fasted state simulated intestinal fluid [84]; XRPD: X-ray powder diffraction.”
MethodHörter, D., & Dressman, J. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00130-7 · Cited by 819 · cited 1×
“Another well-studied approach to improve oral absorption for poorly soluble compounds is to reduce particle size and thereby increase dissolution rate [68,69].”
BackgroundCyclodextrins: Their Future in Drug Formulation and Delivery
Stella, V. J., & Rajewski, R. A. (1997) · Pharmaceutical Research · doi:10.1023/a:1012136608249 · Cited by 697 · cited 3×
“Formulations in cyclodextrin solutions are less likely to undergo precipitation following dilution because of the nature of complexation [51].”
Background
Cited by
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Sjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M. B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.010 · Cited by 279
Amorphous Solid Dispersions: Utilization and Challenges in Drug Discovery and Development
He, Y., & Ho, C. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24541 · Cited by 272
Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs
Bergström, C. A. S., Holm, R., Jørgensen, S. A., Andersson, S. B. E., Artursson, P., Beato, S., Borde, A., Box, K., Brewster, M., Dressman, J., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.10.015 · Cited by 257
Metadata
- Authors
- Neervannan, S.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2006-10
- Volume
- 2
- Issue
- 5
- Pages
- 715-731
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2119639040
- Cited by
- 164
- References
- 52
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.